收稿日期: 2024-02-06
录用日期: 2024-03-25
网络出版日期: 2024-07-28
基金资助
国家重点研发计划(2020YFA0210800);国家自然科学基金国际(地区)合作项目(52161160307)
Observation on the effect of hydrogel probiotics colonized in inflammatory sites in the treatment of inflammatory bowel disease
Received date: 2024-02-06
Accepted date: 2024-03-25
Online published: 2024-07-28
Supported by
National Key R&D Program of China(2020YFA0210800);International (regional) Cooperation Project of National Natural Science Foundation of China(52161160307)
目的·构建负载在富含负电羟基的高聚物聚乙烯醇(polyvinyl alcohol,PVA)/海藻酸盐(alginate,ALG)水凝胶(PVA-ALG)上的益生菌( Escherichia coli Nissle1917,EcN)体系(EcN@PVA-ALG),探究其在结肠炎症部位定植性及其对葡聚糖硫酸钠盐(dextran sulfate sodium salt,DSS)诱导的炎性肠病(inflammatory bowel disease,IBD)的治疗效果。方法·将EcN悬液加入PVA-ALG水凝胶中,过筛离心后得到EcN@PVA-ALG水凝胶益生菌复合物,使用流变仪验证PVA-ALG水凝胶的合成。利用电位仪检测EcN@PVA-ALG的表面电荷,荧光显微镜观察PVA-ALG上的EcN负载情况。通过酶标仪检测EcN@PVA-ALG在600 nm处的吸光度;同时,取EcN@PVA-ALG复合物悬液进行细菌平板计数,检测EcN@PVA-ALG内EcN的生长活力。采用CCK-8法评估EcN@PVA-ALG对HEK293细胞增殖的抑制作用。利用活体成像系统(IVIS)分析PVA-ALG对炎症结肠的富集作用,观察其炎症靶向性能;将EcN负载在PVA-ALG上,再用IVIS观察EcN@PVA-ALG对炎症结肠的富集,观察其在炎症部位的定植能力。建立DSS诱导的IBD小鼠模型,EcN@PVA-ALG组( n=5)每天灌肠给予1×10 8CFU的EcN@PVA-ALG,连续5 d;另设PVA-ALG组、EcN组、PBS组和健康对照组,每组5只。治疗期间,每天记录小鼠的体质量。治疗结束后处死小鼠,取其结肠组织,测量结肠长度;进行疾病活动指数(disease activity index,DAI)评分;检测炎症细胞因子的水平,包括肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素(interleukin,IL)-6、IL-10和转化生长因子-β(transforming growth factor-β,TGF-β);通过苏木精-伊红染色(H-E染色)进行结肠组织的病理评估。结果·PVA-ALG和EcN@PVA-ALG均带负电。EcN成功负载于PVA-ALG,并且PVA-ALG不影响EcN的生长活力;同时,PVA-ALG对正常细胞也具有良好的安全性。与健康对照组相比,PVA-ALG对炎症结肠组织具有超过2倍的富集效果。体内外实验发现,负载EcN的EcN@PVA-ALG复合物对炎症组织的富集效果比未加任何修饰的EcN高8倍。EcN@PVA-ALG治疗后,小鼠体质量迅速恢复,DAI的上升被显著抑制,结肠长度与健康小鼠相近,促炎细胞因子TNF-α、IL-6水平降低而抗炎细胞因子IL-10和TGF-β水平升高,结肠组织隐窝结构恢复。结论·相比于未加修饰的EcN,EcN@PVA-ALG促进了EcN在结肠炎症部位的定植,并使其发挥更好的治疗DSS诱导的IBD的功效。
徐唯 , 李蒙 , 王昊泽 , 崔凯 , 肖泽宇 . 炎症部位定植水凝胶益生菌治疗炎性肠病的效果观察[J]. 上海交通大学学报(医学版), 2024 , 44(7) : 883 -890 . DOI: 10.3969/j.issn.1674-8115.2024.07.009
Objective ·To construct a probiotic ( Escherichia coli Nissle1917,EcN) system (EcN@PVA-ALG) loaded on polyvinyl alcohol (PVA) / alginate (ALG) hydrogel (PVA-ALG) rich in negative hydroxyl groups, and to explore its colonization in the inflammatory site of colon and its therapeutic effect on dextran sulfate sodium salt (DSS)-induced inflammatory bowel disease (IBD). Methods ·EcN suspension was added to the PVA-ALG hydrogel, and then EcN@PVA-ALG hydrogel probiotic complex was obtained after screening and centrifugation. The synthesis of PVA-ALG hydrogel was verified by rheometer. The surface charge of EcN@PVA-ALG was detected by potentiometer and the load of EcN on PVA-ALG was observed by fluorescence microscope. The absorbance of EcN@PVA-ALG at 600 nm was detected by enzyme labeling instrument. Meanwhile, the bacterial plate count of EcN@PVA-ALG complex suspension was taken to study the growth activity of EcN in EcN@PVA-ALG. The CCK-8 kit was used to assess the inhibitory ability of EcN@PVA-ALG on HEK cell proliferation. In vivo imaging system (IVIS) was used to firstly analyze the enrichment of PVA-ALG on inflammatory colon to study its inflammatory targeting property; then EcN was loaded on PVA-ALG, and IVIS was used to observe the enrichment of EcN@PVA-ALG on inflammatory colon to study its ability to colonize the inflammatory site. To establish the model of IBD mice induced by DSS, EcN@PVA-ALG group ( n=5) was given 1×10 8CFU EcN@PVA-ALG every day for 5 d, and PVA-ALG group, EcN group, PBS group and healthy control group with 5 mice were set up. During the treatment, the body mass of the mice was recorded every day. After treatment, the colonic tissue was taken, and the length of colon was measured. The disease activity index (DAI) score was graded. The levels of inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-10 and transforming growth factor-β (TGF-β) were detected, and the pathological evaluation of colonic tissue was made by H-E staining. Results ·Both PVA-ALG and EcN@PVA-ALG were negatively charged. EcN was successfully loaded onto PVA-ALG and PVA-ALG did not affect the growth viability of EcN, which contributed to the subsequent colonization of inflammatory colons. PVA-ALG had a favorable safety profile on normal cells. Compared with healthy controls, PVA-ALG had more than 2-fold enrichment effect on inflammatory colon tissue. In vitro and in vivo experiments revealed that EcN@PVA-ALG complex loaded with EcN had 8 times higher enrichment effect on inflammatory tissue than EcN without any modification. After EcN@PVA-ALG treatment, the body weight of mice recovered rapidly. The increase of DAI was significantly inhibited. The length of colon was similar to that of healthy mice. The levels of TNF- α and IL-6 decreased, while the levels of IL-10 and TGF- β increased. The crypt structure of colon tissue recovered. Conclusion ·Compared to unmodified EcN, EcN@PVA-ALG promotes the colonization of EcN at inflammatory sites of colon and allows it to exert better efficacy on treating DSS-induced IBD.
1 | DANNE C, SKERNISKYTE J, MARTEYN B, et al. Neutrophils: from IBD to the gut microbiota[J]. Nat Rev Gastroenterol Hepatol, 2024, 21: 184-197. |
2 | BISGAARD T H, ALLIN K H, KEEFER L, et al. Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment[J]. Nat Rev Gastroenterol Hepatol, 2022, 19: 717-726. |
3 | SCOTT B M, GUTIéRREZ-VáZQUEZ C, SANMARCO L M, et al. Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease[J]. Nat Med, 2021, 27: 1212-1222. |
4 | NEURATH M F. Current and emerging therapeutic targets for IBD[J]. Nat Rev Gastroenterol Hepatol, 2017, 14: 269-278. |
5 | LE BERRE C, HONAP S, PEYRIN-BIROULET L. Ulcerative colitis [J]. Lancet, 2023, 402(10401): 571-584. |
6 | KOBAYASHI T, HIBI T. Improving IBD outcomes in the era of many treatment options[J]. Nat Rev Gastroenterol Hepatol, 2023, 20: 79-80. |
7 | MAO R, CHEN M H. Precision medicine in IBD: genes, drugs, bugs and omics[J]. Nat Rev Gastroenterol Hepatol, 2022, 19: 81-82. |
8 | COLOMBEL J F, SANDBORN W J, REINISCH W, et al. Infliximab, azathioprine, or combination therapy for Crohn′s disease[J]. N Engl J Med, 2010, 362(15): 1383-1395. |
9 | CURVINO E J, ROE E F, FREIRE HADDAD H, et al. Engaging natural antibody responses for the treatment of inflammatory bowel disease via phosphorylcholine-presenting nanofibres[J]. Nat Biomed Eng, 2024, 8: 628-649. |
10 | HILL C, GUARNER F, REID G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic[J]. Nat Rev Gastroenterol Hepatol, 2014, 11: 506-514. |
11 | SALMINEN S, COLLADO M C, ENDO A, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics[J]. Nat Rev Gastroenterol Hepatol, 2021, 18: 649-667. |
12 | BUTEL M J. Probiotics, gut microbiota and health[J]. Med Mal Infect, 2014, 44(1): 1-8. |
13 | LUO H, WU F, WANG X, et al. Encoding bacterial colonization and therapeutic modality by wrapping with an adhesive drug-loadable nanocoating[J]. Mater Today, 2023, 62: 98-110. |
14 | SONG W F, YAO W Q, CHEN Q W, et al. In situ bioorthogonal conjugation of delivered bacteria with gut inhabitants for enhancing probiotics colonization[J]. ACS Cent Sci, 2022, 8(9): 1306-1317. |
15 | KURTZ C B, MILLET Y A, PUURUNEN M K, et al. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans[J]. Sci Transl Med, 2019, 11(475): eaau7975. |
16 | WANG X, CAO Z, ZHANG M, et al. Bioinspired oral delivery of gut microbiota by self-coating with biofilms[J]. Sci Adv, 2020, 6(26): eabb1952. |
17 | CARONE M, SPALINGER M R, GAULTNEY R A, et al. Temperature-triggered in situ forming lipid mesophase gel for local treatment of ulcerative colitis[J]. Nat Commun, 2023, 14: 3489. |
18 | YASMIN F, NAJEEB H, SHAIKH S, et al. Novel drug delivery systems for inflammatory bowel disease[J]. World J Gastroenterol, 2022, 28(18): 1922-1933. |
19 | LIU H, CAI Z, WANG F, et al. Colon-targeted adhesive hydrogel microsphere for regulation of gut immunity and flora[J]. Adv Sci, 2021, 8(18): e2101619. |
20 | HUANG H B, GONG W, HOU Y Y, et al. Mucoadhesive hydrogel with anti-gastric acid and sustained-release functions for amelioration of DSS-induced ulcerative colitis[J]. J Agric Food Chem, 2023, 71(9): 4016-4028. |
21 | ZHANG K, ZHU L, ZHONG Y, et al. Prodrug integrated envelope on probiotics to enhance target therapy for ulcerative colitis[J]. Adv Sci (Weinh), 2023, 10(4): e2205422. |
22 | ZHANG S, ERMANN J, SUCCI M D, et al. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease[J]. Sci Transl Med, 2015, 7(300): 300ra128. |
23 | MING Z, HAN L, BAO M, et al. Living bacterial hydrogels for accelerated infected wound healing[J]. Adv Sci (Weinh), 2021, 8(24): e2102545. |
/
〈 |
|
〉 |